FRANKFURT, Germany (AP) — Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday ...

Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Novo Nordisk (NYSE:NVO) shares dropped 5% in early trading on Monday after Eli Lilly (NYSE:LLY) released new trial data showing its weight loss drug, Zepbound, delivered stronger results than Wegovy.

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...